Evidence map›Paper›PMID 31523618›Full record

ArticleBalkan journal of medical genetics : BJMG2019

Cystic Fibrosis Mutation Spectrum in North Macedonia: A Step Toward Personalized Therapy.

M Terzic, M Jakimovska, S Fustik, T Jakovska, E Sukarova-Stefanovska, D Plaseska-Karanfilska

Open access · goldAbstract read
In one paragraph

Article in Balkan journal of medical genetics : BJMG, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Hyperinflammation and airway surface liquid dehydration in cystic fibrosis: purinergic system as therapeutic target.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

M TerzicResearch Center for Genetic Engineering and Biotechnology "Georgi D.Efremov," Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia.
M JakimovskaResearch Center for Genetic Engineering and Biotechnology "Georgi D.Efremov," Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia.
S FustikUniversity Children's Hospital Skopje, Skopje, Republic of North Macedonia.
T JakovskaInstitute of Respiratory Diseases in Children, Kozle, Skopje, Republic of North Macedonia.
E Sukarova-StefanovskaResearch Center for Genetic Engineering and Biotechnology "Georgi D.Efremov," Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia.
D Plaseska-KaranfilskaResearch Center for Genetic Engineering and Biotechnology "Georgi D.Efremov," Macedonian Academy of Sciences and Arts, Skopje, Republic of North Macedonia.
Macedonian Academy of Sciences and Arts · MKInstitute of public health of Republic of Macedonia · MKPHI University Psychiatric Clinic - Skopje · MK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most prevalent "rare" disease worldwide, cystic fibrosis (CF), is an autosomal recessive multisystem disease, caused by mutations in the

Indexed as

CFTR mutation classesCystic fibrosis (CF)Mutations

Identifiers

PMID31523618
PMCPMC6714339
OpenAlexW2970983864

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.